BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37259600)

  • 1. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan.
    Sugiura K; Hiratsuka H; Oshima G; Aiko S
    Jpn J Clin Oncol; 2023 Jul; 53(8):691-697. PubMed ID: 37259600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
    Zhu C; Han G; Wu B
    BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
    Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M
    J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer.
    Sugiura K; Seo Y; Takahashi T; Tokura H; Ito Y; Tanaka M; Kishida N; Nishi Y; Onishi Y; Aoki H
    BMC Gastroenterol; 2021 Apr; 21(1):184. PubMed ID: 33879100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF.
    Giuliani J; Mandara M; Mantoan B; Ferrario L; Mangiola D; Napoli G; Muraro M; Fiorica F
    J Oncol Pharm Pract; 2023 Jun; 29(4):958-961. PubMed ID: 36823960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
    Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
    J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
    Cho SK; Hay JW; Barzi A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
    Kim J; Lim J; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim DY
    Gynecol Oncol; 2023 Dec; 179():106-114. PubMed ID: 37976756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
    Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
    Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
    Patel KK; Stein S; Lacy J; O'Hara M; Huntington SF
    JAMA Netw Open; 2021 Jan; 4(1):e2033441. PubMed ID: 33433598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
    Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
    Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland.
    Barbier MC; Pardo E; Panje CM; Gautschi O; Lupatsch JE;
    Eur J Health Econ; 2021 Jul; 22(5):669-677. PubMed ID: 33745093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 19. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    She L; Tian K; Han J; Zuo W; Wang Z; Zhang N
    Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer.
    Chongqing T; Sini L; Xiaohui Z; Liubao P; Ye P; Shuxia Q; Liting W; Meiyu W; Xiaomin W
    Front Pharmacol; 2021; 12():802942. PubMed ID: 34970153
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.